Wei Li & Li Wan. (2022). Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China. Frontiers Media S.A..
Chicago Style (17th ed.) CitationWei Li and Li Wan. Cost-effectiveness Analysis of Sugemalimab Vs. Placebo, in Combination with Chemotherapy, for Treatment of First-line Metastatic NSCLC in China. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationWei Li and Li Wan. Cost-effectiveness Analysis of Sugemalimab Vs. Placebo, in Combination with Chemotherapy, for Treatment of First-line Metastatic NSCLC in China. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.